JP2023522883A - 神経学的障害を処置するための組成物および方法 - Google Patents

神経学的障害を処置するための組成物および方法 Download PDF

Info

Publication number
JP2023522883A
JP2023522883A JP2022562939A JP2022562939A JP2023522883A JP 2023522883 A JP2023522883 A JP 2023522883A JP 2022562939 A JP2022562939 A JP 2022562939A JP 2022562939 A JP2022562939 A JP 2022562939A JP 2023522883 A JP2023522883 A JP 2023522883A
Authority
JP
Japan
Prior art keywords
subject
raav
nucleic acid
viral vector
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562939A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522883A5 (cg-RX-API-DMAC7.html
Inventor
ベイリー,レイチェル,エム.
グレイ,スティーヴン,ジェイ.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of JP2023522883A publication Critical patent/JP2023522883A/ja
Publication of JP2023522883A5 publication Critical patent/JP2023522883A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022562939A 2020-04-15 2021-04-14 神経学的障害を処置するための組成物および方法 Pending JP2023522883A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063010179P 2020-04-15 2020-04-15
US63/010,179 2020-04-15
PCT/US2021/027266 WO2021211700A1 (en) 2020-04-15 2021-04-14 Compositions and methods for treatment of neurological disorders

Publications (2)

Publication Number Publication Date
JP2023522883A true JP2023522883A (ja) 2023-06-01
JP2023522883A5 JP2023522883A5 (cg-RX-API-DMAC7.html) 2024-04-15

Family

ID=78081428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562939A Pending JP2023522883A (ja) 2020-04-15 2021-04-14 神経学的障害を処置するための組成物および方法

Country Status (9)

Country Link
US (2) US11753655B2 (cg-RX-API-DMAC7.html)
EP (1) EP4135661A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023522883A (cg-RX-API-DMAC7.html)
KR (1) KR20230004617A (cg-RX-API-DMAC7.html)
CN (1) CN115715185A (cg-RX-API-DMAC7.html)
AU (1) AU2021255934A1 (cg-RX-API-DMAC7.html)
CA (1) CA3175406A1 (cg-RX-API-DMAC7.html)
IL (1) IL296857A (cg-RX-API-DMAC7.html)
WO (1) WO2021211700A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296857A (en) * 2020-04-15 2022-11-01 Univ Texas Preparations and methods for the treatment of neurological disorders
WO2023102518A1 (en) * 2021-12-03 2023-06-08 The Board Of Regents Of The University Of Texas System Gnao1 gene therapy vectors and uses thereof
EP4713462A1 (en) * 2023-05-18 2026-03-25 Gencorrex Therapies Inc. Solute carrier family 6 member 8 vectors and methods for use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531926A (ja) * 2015-09-17 2018-11-01 コーダ バイオセラピューティクス, インコーポレイテッド 神経学的障害を処置するための組成物および方法
WO2020033833A1 (en) * 2018-08-10 2020-02-13 The University Of North Carolina At Chapel Hill Optimized cln7 genes and expression cassettes and their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8676330B2 (en) * 2009-03-20 2014-03-18 ElectroCore, LLC Electrical and magnetic stimulators used to treat migraine/sinus headache and comorbid disorders
US20070292922A1 (en) * 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
US9221890B2 (en) * 2011-10-25 2015-12-29 Indiana University Research And Technology Corporation Gigaxonin fusion protein and methods for treating giant axonal neuropathy
WO2015060722A1 (en) * 2013-10-24 2015-04-30 Uniqure Ip B.V. Aav-5 pseudotyped vector for gene therapy for neurological diseases
US10016514B2 (en) * 2015-05-15 2018-07-10 New Hope Research Foundation Polynucleotides, vectors and methods for insertion and expression of transgenes
CA3045551A1 (en) * 2016-12-16 2018-06-21 Uniqure Ip B.V. Immunoadsorption
IL296857A (en) * 2020-04-15 2022-11-01 Univ Texas Preparations and methods for the treatment of neurological disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531926A (ja) * 2015-09-17 2018-11-01 コーダ バイオセラピューティクス, インコーポレイテッド 神経学的障害を処置するための組成物および方法
WO2020033833A1 (en) * 2018-08-10 2020-02-13 The University Of North Carolina At Chapel Hill Optimized cln7 genes and expression cassettes and their use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GLIA, vol. 68, JPN6025013307, 27 December 2019 (2019-12-27), pages 1241 - 1254, ISSN: 0005711786 *
MOLECULAR THERAPY, vol. 28(4), Suppl. 1, JPN6025013309, 28 April 2020 (2020-04-28), pages 406 - 407, ISSN: 0005563362 *
MOLECULAR THERAPY: METHODS & CLINICAL DEVELOPMENT, vol. 9, JPN6025013311, 2018, pages 160 - 171, ISSN: 0005711787 *
NATURE GENETICS, vol. 26, JPN6025013308, 2000, pages 370 - 374, ISSN: 0005711788 *
NEURODEGENERATIVE DISEASES, vol. 15, Supp.1, JPN6025013310, 2015, pages 1210 - 5, ISSN: 0005563363 *

Also Published As

Publication number Publication date
AU2021255934A1 (en) 2022-10-20
US20210324411A1 (en) 2021-10-21
WO2021211700A1 (en) 2021-10-21
US12534741B2 (en) 2026-01-27
KR20230004617A (ko) 2023-01-06
IL296857A (en) 2022-11-01
CN115715185A (zh) 2023-02-24
US11753655B2 (en) 2023-09-12
EP4135661A4 (en) 2024-07-10
US20240102050A1 (en) 2024-03-28
EP4135661A1 (en) 2023-02-22
CA3175406A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
JP2022515338A (ja) 遺伝子送達のための組み換えアデノ随伴ウイルスベクター
US20240376498A1 (en) Transgene cassettes, aav vectors and aav viral vectors for the expression of human codon-optimized slc6a1
US12534741B2 (en) Compositions and methods for treatment of neurological disorders
JP7702949B2 (ja) ヒトmecp2遺伝子を発現するように設計されたトランスジーンカセット
US20240269161A1 (en) Methods and compositions for tau reduction gene therapy
JP2023534026A (ja) 多部分遺伝子送達のための組み換えアデノ随伴ウイルスベクター
US20250283111A1 (en) Recombinant adeno-associated viral vector for gene delivery
EP4188404A1 (en) Transgene cassettes, aav vectors, and aav viral vectors for expression of human codon-optimized cstb
WO2024220719A1 (en) Modified aav capsids for gene delivery
US20260131024A1 (en) Gene therapy for prader willi syndrome
US20240342314A1 (en) Slc13a5 gene therapy vectors and uses thereof
WO2023102406A1 (en) Vector genome design to express optimized cln7 transgene
WO2024163335A2 (en) Pten gene therapy vectors and uses thereof
CN118019855A (zh) Slc13a5基因治疗载体及其用途
WO2023102518A1 (en) Gnao1 gene therapy vectors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250630

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250823

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251021